ResultsQ4FY26

Pat Growth 25pctEbitda Margin CompressionExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

KIMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹766.00

prior close

₹748.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.5%-4.7% vs market

Hospital peers, median of 25sector-0.5%-5.7% vs sector

On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 5.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.2

15m

+0.3

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1-1.5-4.7-0.5-5.7

Next day

-3.4-0.3-3.0+0.7-4.1

-2.3-0.3-2.1+0.2-2.6

+0.5+0.4+0.1+0.9-0.4

-1.0+0.3-1.3+0.3-1.3

-1.6+1.5-3.1+1.0-2.6

+2.4+2.3+0.1+0.1+2.3

15d

+2.0+1.5+0.4+2.4-0.4

+3.1+5.3-2.2+3.2-0.1

+3.3+7.8-4.5+5.0-1.7

+5.0+9.7-4.7+7.9-2.9

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

KIMS reported Q4FY26 results with standalone revenue of Rs. 4,317 million, up 18% YoY from Rs. 3,662 million in Q4FY25. Net profit grew 34% to Rs. 330 million from Rs. 246 million. For the full year, revenue was Rs. 16,120 million (up 12% from Rs. 14,433 million) with net profit of Rs. 2,346 million. The auditor gave an unmodified (clean) opinion on both standalone and consolidated results. There was a one-time exceptional charge of Rs. 74 million due to changes in Labour Codes. Management changes include appointment of new CFO, Company Secretary, and Chief Risk Officer, plus re-designation of Mr. Adwik Bollineni as Executive Director.

Likely market impact

Strong Q4 with 34% PAT growth is positive for shareholders, but full-year EBITDA margins compressed from 57.5% to 50.8%, which may concern investors focused on profitability trends.